As it builds up its preclinical pipeline, Abeona is switching gears to create chimeric AAV vectors that it hopes will do a better job than naturally occurring ones of dialing in the right properties for the right indication. A big win would be to finally gain gene therapy a foothold in cystic fibrosis.
On April 30, Abeona Therapeutics Inc. presented data at the American Society for Cell and Gene Therapy meeting in Washington, showing one of the company’s chimeric AAV capsids can deliver a functional copy of the CFTR gene to mouse lungs and can correct chloride ion transport in airway cells from cystic fibrosis (CF) patients.
Abeona has been developing gene therapies for rare diseases since its inception, but it began with non-engineered vectors. Launched as Abeona Therapeutics LLC in 2013, the company was acquired by PlasmaTech Biopharmaceuticals Inc. in 2015 and went public the same year under its new name Abeona Therapeutics Inc.
Its lead program, which is expected to enter Phase III mid-year, uses a retroviral vector to deliver the COL7A1 gene to treat the rare skin disorder recessive dystrophic